| Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. | |
| | |
MedLine Citation:
|
PMID: 18670224 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess hematologic and hepatic toxicities associated with in utero and breastfeeding exposure to maternal highly active antiretroviral therapy (HAART) among infants in Botswana. DESIGN: A nested cohort study within a randomized clinical trial (the Mashi Study). Laboratory toxicities among infants born to women who initiated HAART before delivery were compared with toxicities among those born to women who received zidovudine and a single dose of nevirapine or placebo in labor. Infants were randomized to breastfeed with extended zidovudine or to formula-feed. METHODS: Hemoglobin concentrations, absolute neutrophil and platelet counts, and alanine aminotransferase and aspartate aminotransferase levels were recorded from birth to 7 months of age in infants. Grade 3 and 4 toxicities were compared by infant antiretroviral exposure status. RESULTS: In-utero exposure to maternal HAART was associated with increased risk for neutropenia in infants up to 1 month of age; 21.7% of HAART-exposed infants were neutropenic, compared with 5.5% of the infants exposed to zidovudine (P < 0.01). However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age. Postnatal exposure to HAART was not associated with hematologic or hepatic toxicities. Laboratory toxicities were clinically asymptomatic in all but one infant. CONCLUSION: Exposure to maternal HAART in utero may increase the risk for infant neutropenia, particularly among breastfed infants, but the clinical significance of this finding is uncertain. The lack of association between exposure to HAART through breastfeeding and long-term toxicities in infants is reassuring but deserves study in larger cohorts. |
| | |
Authors:
|
Woong Hwan Bae; Carolyn Wester; Laura M Smeaton; Roger L Shapiro; Shahin Lockman; Kenneth Onyait; Ibou Thior; Max Essex |
Related Documents
:
|
19772374 - Early exclusive breastfeeding and maternal attitudes towards infant feeding in a popula... 20929494 - The infant feeding intentions scale demonstrates construct validity and comparability i... 21254794 - Successful relactation--a case history. 12033074 - Cup or bottle for preterm infants: effects on oxygen saturation, weight gain, and breas... 22268644 - Time to consider a new treatment protocol for aggressive posterior retinopathy of prema... 3009074 - Congenital anomalies--retrospective and contemporary treatment. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: AIDS (London, England) Volume: 22 ISSN: 1473-5571 ISO Abbreviation: AIDS Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-08-01 Completed Date: 2008-09-24 Revised Date: 2011-05-05 |
Medline Journal Info:
|
Nlm Unique ID: 8710219 Medline TA: AIDS Country: England |
Other Details:
|
Languages: eng Pagination: 1633-40 Citation Subset: IM; X |
Affiliation:
|
Harvard College, Harvard Faculty of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alanine Transaminase
/
blood Anti-HIV Agents / adverse effects*, therapeutic use Anti-Retroviral Agents / adverse effects*, therapeutic use Antiretroviral Therapy, Highly Active / adverse effects Aspartate Aminotransferases / blood Biological Markers / blood Botswana Breast Feeding Cohort Studies Female Follow-Up Studies HIV Infections / drug therapy*, immunology, transmission* HIV-1* Hemoglobins / analysis Humans Infant Infant, Newborn Infectious Disease Transmission, Vertical Male Neutropenia / etiology, immunology Nevirapine / adverse effects, therapeutic use Platelet Count Pregnancy Pregnancy Complications, Infectious / drug therapy*, immunology Prenatal Exposure Delayed Effects Zidovudine / adverse effects, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
K23 HD049292/HD/NICHD NIH HHS; K23 HD049292-03/HD/NICHD NIH HHS; R01 HD037793-05/HD/NICHD NIH HHS; R01 HD37793/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/Anti-Retroviral Agents; 0/Biological Markers; 0/Hemoglobins; 129618-40-2/Nevirapine; 30516-87-1/Zidovudine; EC 2.6.1.1/Aspartate Aminotransferases; EC 2.6.1.2/Alanine Transaminase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.
Next Document: HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural popula...